Inventor · disambiguated record
Mark E. Fitzgerald
Also filed as: FITZGERALD MARK · FITZGERALD MARK E
15 granted patents·10 pending applications·93 citations·filing 2004–2025
91Inventor score
Files withC4 THERAPEUTICS INC8BAYER AG7BROAD INST INC3CALICO LIFE SCIENCES LLC3NESTED THERAPEUTICS INC3
Top patents by PatentIndex Score
25 records- 0196US10905768B1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Feb 2, 2021·31 cites·20 claims
- 0296US10646575B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 12, 2020·32 cites·28 claims
- 0393US11492358B1Macrocyclic indole derivativesBAYER AG·Filed 2021·Granted Nov 8, 2022·3 cites·18 claims
- 0492US10981932B2Macrocyclic indole derivativesBAYER AG·Filed 2017·Granted Apr 20, 2021·9 cites·17 claims
- 0590US11891404B2Substituted macrocyclic indole derivativesBAYER AG·Filed 2022·Granted Feb 6, 2024·1 cites·10 claims
- 0688US12152041B2Macrocyclic fluorine substituted indole derivativesBROAD INST INC·Filed 2022·Granted Nov 26, 2024·1 cites·6 claims
- 0787US11440923B2Substituted macrocyclic indole derivativesBAYER AG·Filed 2018·Granted Sep 13, 2022·3 cites·15 claims
- 0886US11478451B1Macrocyclic chlorine substituted indole derivativesBAYER AG·Filed 2018·Granted Oct 25, 2022·3 cites·16 claims
- 0986US11401278B2Macrocyclic indole derivativesBROAD INST INC·Filed 2018·Granted Aug 2, 2022·3 cites·13 claims
- 1085US12076405B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Sep 3, 2024·1 cites·20 claims
- 1185US11447504B2Macrocyclic chlorine substituted indole derivativesBAYER AG·Filed 2018·Granted Sep 20, 2022·3 cites·14 claims
- 1285US11286263B2Macrocyclic fluorine substituted indole derivativesBROAD INST INC·Filed 2018·Granted Mar 29, 2022·3 cites·9 claims
- 1383US2025121069A1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1481US12486253B2Therapeutics for the degradation of mutant BRAFC4 THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·0 cites·4 claims
- 1570US2024199581A1Therapeutics for the degradation of mutant brafC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1664US2025120961A1P53 modulatorsNESTED THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1761US12454521B2Targeted protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Oct 28, 2025·0 cites·25 claims
- 1861US2025289811A1Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitorsNESTED THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1958US2024424111A1Degrader Compounds and Uses ThereofCALICO LIFE SCIENCES LLC·Filed 2022·Application pending·0 cites
- 2058US2025302815A1Protein tyrosine phosphatase targeting ligandsCALICO LIFE SCIENCES LLC·Filed 2022·Application pending·0 cites
- 2156US2023233692A1Compounds for targeted degradation of retC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2251US2024383886A1Protein Tyrosine Phosphatase Degraders and Methods of Use ThereofCALICO LIFE SCIENCES LLC·Filed 2020·Application pending·0 cites
- 2344US7550474B2Substituted phenyl acetamides and their use as protease inhibitorsJOHNSON & JOHNSON PHARM RES·Filed 2004·Granted Jun 23, 2009·0 cites·42 claims
- 2444US2025288571A1Mitogen-activated protein kinase (mek) inhibitorsNESTED THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2543US2021253598A1Aryl annulated macrocyclic indole derivativesBAYER AG·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark E. Fitzgerald files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →